• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

口腔替比培南-阿维巴坦在鼠分枝杆菌肺感染模型中的活性。

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.

机构信息

Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.

Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.

出版信息

Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. doi: 10.1128/aac.01459-22. Epub 2023 Jan 23.

DOI:10.1128/aac.01459-22
PMID:36688684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9933631/
Abstract

The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus . Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection. The results suggest that tebipenem-avibactam presents an attractive oral drug candidate pair for the treatment of M. abscessus pulmonary disease and could inform the design of clinical trials.

摘要

β-内酰胺类药物替比培南与β-内酰胺酶抑制剂阿维巴坦联合使用对脓肿分枝杆菌具有强大的杀菌活性。在这里，我们报告称，相应的口服前药替比培南 pivoxil 和阿维巴坦 ARX-1796 的联合使用在脓肿分枝杆菌肺部感染的小鼠模型中显示出疗效。结果表明，替比培南-阿维巴坦组合是一种有吸引力的治疗脓肿分枝杆菌肺病的口服候选药物对，并为临床试验的设计提供了信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2842/9933631/f2a535eca744/aac.01459-22-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2842/9933631/be7a52bf7486/aac.01459-22-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2842/9933631/f2a535eca744/aac.01459-22-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2842/9933631/be7a52bf7486/aac.01459-22-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2842/9933631/f2a535eca744/aac.01459-22-f002.jpg

相似文献

1
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection.口腔替比培南-阿维巴坦在鼠分枝杆菌肺感染模型中的活性。
Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. doi: 10.1128/aac.01459-22. Epub 2023 Jan 23.
2
effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical isolates.新型口服β-内酰胺酶抑制剂头孢洛布坦与口服β-内酰胺类药物联合对临床分离株的作用。
Microbiol Spectr. 2024 Jul 2;12(7):e0008424. doi: 10.1128/spectrum.00084-24. Epub 2024 Jun 6.
3
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.强烈杀菌的全口服β-内酰胺类药物联合治疗用于治疗脓肿分枝杆菌肺病。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0079022. doi: 10.1128/aac.00790-22. Epub 2022 Sep 1.
4
Dual β-lactam therapy to improve treatment outcome in Mycobacterium abscessus disease.双联β-内酰胺疗法改善脓肿分枝杆菌病的治疗结局。
Clin Microbiol Infect. 2024 Jun;30(6):738-742. doi: 10.1016/j.cmi.2024.03.019. Epub 2024 Mar 23.
5
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.阿维巴坦与碳青霉烯类药物联合使用对耐药脓肿分枝杆菌显示出增强的抗菌效力。
Future Microbiol. 2017 May;12(6):473-480. doi: 10.2217/fmb-2016-0234. Epub 2017 Feb 16.
6
The activity of carbapenems alone and in combination with β-lactamase inhibitors against difficult-to-treat mycobacteria; and complex: A systematic review.碳青霉烯类单独及与β-内酰胺酶抑制剂联合应用对难治疗分枝杆菌及复合体的活性：一项系统评价
Int J Mycobacteriol. 2023 Jul-Sep;12(3):211-225. doi: 10.4103/ijmy.ijmy_131_23.
7
The addition of avibactam renders piperacillin an effective treatment for infection in an in vivo model.阿维巴坦的加入使哌拉西林在体内模型中对感染有了有效的治疗作用。
Antimicrob Resist Infect Control. 2018 Dec 13;7:151. doi: 10.1186/s13756-018-0448-4. eCollection 2018.
8
Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice.环己基格雷西霉素对小鼠中的脓肿分枝杆菌具有活性。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0140021. doi: 10.1128/AAC.01400-21. Epub 2021 Nov 1.
9
High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against nontuberculous mycobacteria in vitro and in vivo.F-ATP 合酶抑制剂 TBAJ-5307 在体外和体内对非结核分枝杆菌具有高效性。
J Biol Chem. 2024 Feb;300(2):105618. doi: 10.1016/j.jbc.2023.105618. Epub 2024 Jan 3.
10
Indole-2-Carboxamides Are Active against in a Mouse Model of Acute Infection.吲哚-2-羧酰胺类化合物在急性感染的小鼠模型中具有活性。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02245-18. Print 2019 Mar.

引用本文的文献

1
Activity of combinations of bactericidal and bacteriostatic compounds in -infected mice: an overview.感染小鼠中杀菌和抑菌化合物组合的活性：综述。
Front Microbiol. 2025 Aug 1;16:1616149. doi: 10.3389/fmicb.2025.1616149. eCollection 2025.
2
The addition of amoxicillin improves the efficacy of the imipenem-avibactam combination against in a mouse model of infection.在小鼠感染模型中，添加阿莫西林可提高亚胺培南-阿维巴坦联合用药对[具体病原体未给出]的疗效。
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0053425. doi: 10.1128/aac.00534-25. Epub 2025 Jul 21.
3
Toward a Bactericidal Oral Drug Combination for the Treatment of Lung Disease.

本文引用的文献

1
Nontuberculous Mycobacteria Lung Disease (NTM-LD): Current Recommendations on Diagnosis, Treatment, and Patient Management.非结核分枝杆菌肺病（NTM-LD）：关于诊断、治疗和患者管理的当前建议
Int J Gen Med. 2022 Oct 1;15:7619-7629. doi: 10.2147/IJGM.S272690. eCollection 2022.
2
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.强烈杀菌的全口服β-内酰胺类药物联合治疗用于治疗脓肿分枝杆菌肺病。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0079022. doi: 10.1128/aac.00790-22. Epub 2022 Sep 1.
3
Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue.
研发用于治疗肺部疾病的杀菌性口服药物组合。
ACS Infect Dis. 2025 Apr 11;11(4):929-939. doi: 10.1021/acsinfecdis.4c00948. Epub 2025 Apr 1.
4
Antibacterials with Novel Chemical Scaffolds in Clinical Development.处于临床开发阶段的具有新型化学骨架的抗菌药物。
Drugs. 2025 Mar;85(3):293-323. doi: 10.1007/s40265-024-02137-x. Epub 2025 Jan 23.
5
Toward better cures for lung disease.寻求更好的肺部疾病治疗方法。
Clin Microbiol Rev. 2024 Dec 10;37(4):e0008023. doi: 10.1128/cmr.00080-23. Epub 2024 Oct 3.
6
Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable.从未经授权的商业供应商处采购的用于研究的奥马环素粉末可能不纯和/或不稳定。
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0063824. doi: 10.1128/aac.00638-24. Epub 2024 Jun 18.
7
effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical isolates.新型口服β-内酰胺酶抑制剂头孢洛布坦与口服β-内酰胺类药物联合对临床分离株的作用。
Microbiol Spectr. 2024 Jul 2;12(7):e0008424. doi: 10.1128/spectrum.00084-24. Epub 2024 Jun 6.
8
Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.抗分枝杆菌药物治疗脓肿分枝杆菌肺部感染的临床前小鼠模型：当前的实践和建议。
Tuberculosis (Edinb). 2024 Jul;147:102503. doi: 10.1016/j.tube.2024.102503. Epub 2024 Mar 19.
9
Therapy of Infections in Solid Organ Transplant Patients.实体器官移植患者感染的治疗
Microorganisms. 2024 Mar 16;12(3):596. doi: 10.3390/microorganisms12030596.
10
Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.利用可再利用药物和天然产物中的潜在先导化合物来应对非结核分枝杆菌。
Curr Top Med Chem. 2024;24(15):1291-1326. doi: 10.2174/0115680266276938240108060247.
非结核分枝杆菌肺病药物研发的挑战：结核来拯救。
J Exp Med. 2022 Jun 6;219(6). doi: 10.1084/jem.20220445. Epub 2022 May 11.
4
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.口服氢溴酸替比培南酯治疗复杂性尿路感染
N Engl J Med. 2022 Apr 7;386(14):1327-1338. doi: 10.1056/NEJMoa2105462.
5
The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant spp.替比培南匹伏酯重新用作广泛耐药菌引起的严重胃肠道感染的替代疗法
Elife. 2022 Mar 15;11:e69798. doi: 10.7554/eLife.69798.
6
Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice.环己基格雷西霉素对小鼠中的脓肿分枝杆菌具有活性。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0140021. doi: 10.1128/AAC.01400-21. Epub 2021 Nov 1.
7
Tebipenem pivoxil hydrobromide-No PICC, no problem!替比培南倍他米隆氢溴酸盐-无需 PICC，无问题！
Pharmacotherapy. 2021 Sep;41(9):748-761. doi: 10.1002/phar.2614. Epub 2021 Aug 17.
8
Treatment of Mycobacterium abscessus Pulmonary Disease.脓肿分枝杆菌肺病的治疗
Chest. 2022 Jan;161(1):64-75. doi: 10.1016/j.chest.2021.07.035. Epub 2021 Jul 24.
9
in cystic fibrosis.在囊性纤维化中。
Science. 2021 Apr 30;372(6541):465-466. doi: 10.1126/science.abi5695.
10
Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.抗分枝杆菌小分子药物研发管道：再利用药物和有前途的新型化学实体。
Med Res Rev. 2021 Jul;41(4):2350-2387. doi: 10.1002/med.21798. Epub 2021 Mar 1.